BlueGnome develops tests and software to investigate genetic disorders, focusing on intellectual disability, cancer and infertility. The company was spun out of Cambridge University post-doctoral research in 2002 by Nick Haan and Graham Snudden, who still lead the business. The company is backed by Cambridge University, as well as The University Challenge Fund and The Wellcome Trust. Sales of its IVF applications to medical institutions and clinics around the world are particularly strong, and have helped sales grow 65% a year from £2.7m in 2008 to £11.8m in 2011.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.